Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Personalized Medicine in Breast Cancer: Pharmacogenomics Approaches Publisher



Jeibouei S1 ; Akbari ME2 ; Kalbasi A3 ; Aref AR4, 5 ; Ajoudanian M6 ; Rezvani A7 ; Zali H8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
  4. 4. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, United States
  5. 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
  6. 6. Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Hematology, Medical Oncology and Stem Cell Transplantation, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  8. 8. Proteomics Research Centre, Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Pharmacogenomics and Personalized Medicine Published:2019


Abstract

Breast cancer is the fifth cause of cancer death among women worldwide and represents a global health concern due to the lack of effective therapeutic regimens that could be applied to all disease groups. Nowadays, strategies based on pharmacogenomics constitute novel approaches that minimize toxicity while maximizing drug efficacy; this being of high importance in the oncology setting. Besides, genetic profiling of malignant tumors can lead to the development of targeted therapies to be included in effective drug regimens. Advances in molecular diagnostics have revealed that breast cancer is a multifaceted disease, characterized by inter-tumoral and intra-tumoral heterogeneity and, unlike the past, molecular classifications based on the expression of individual biomarkers have led to devising novel therapeutic strategies that improve patient survival. In this review, we report and discuss the molecular classification of breast cancer subtypes, the heterogeneity resource, and the advantages and disadvantages of current drug regimens with consideration of pharmacogenomics in response and resistance to treatment. © 2019 Jeibouei et al.
Related Docs
View other Related Docs
1. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
2. Microrna As a Systemic Intervention in the Specific Breast Cancer Subtypes With C-Myc Impacts; Introducing Subtype-Based Appraisal Tool, Journal of Cellular Physiology (2018)
3. Can Color and Spectral Doppler Ultrasound of Breast Cancers Help to Predict the Immunohistochemistry Profile?, Archives of Breast Cancer (2019)
4. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
5. Evaluation of Exosomal Mir-9 and Mir-155 Targeting Pten and Dusp14 in Highly Metastatic Breast Cancer and Their Effect on Low Metastatic Cells, Journal of Cellular Biochemistry (2019)
6. Muc1 Is a Potential Target to Overcome Trastuzumab Resistance in Breast Cancer Therapy, Cancer Cell International (2022)
7. Pathogenesis of Breast Cancer Metastasis to Brain: A Comprehensive Approach to the Signaling Network, Molecular Neurobiology (2016)
8. Emerging Roles of Exosomal Mirnas in Breast Cancer Drug Resistance, IUBMB Life (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (2)
Seyed Mohammad Tavangar (2)
Other Related Docs
9. Isolation and Characterization of the Primary Epithelial Breast Cancer Cells and the Adjacent Normal Epithelial Cells From Iranian Women’S Breast Cancer Tumors, Cytotechnology (2018)
10. Notch Signaling Pathway: A Comprehensive Prognostic and Gene Expression Profile Analysis in Breast Cancer, BMC Cancer (2022)
11. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)
12. Breast Cancer in the Era of Precision Medicine, Molecular Biology Reports (2022)
13. Exosomal Mirnas From Highly Metastatic Cells Can Induce Metastasis in Non-Metastatic Cells, Life Sciences (2019)
14. Piwi-Interacting Rnas: New Biomarkers for Diagnosis and Treatment of Breast Cancer, Cell and Bioscience (2020)
15. Comparative Analysis of Protein-Protein Interaction Networks in Metastatic Breast Cancer, PLoS ONE (2022)
16. Long-Term Outcomes of Non-Metastatic Breast Cancer Patients by Molecular Subtypes, BMC Women's Health (2022)
17. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
18. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
19. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance Is Required, Current Cancer Drug Targets (2018)
20. Empagliflozin Treatment of Cardiotoxicity: A Comprehensive Review of Clinical, Immunobiological, Neuroimmune, and Therapeutic Implications, Biomedicine and Pharmacotherapy (2023)
21. Comparison of Brca1 Expression Between Triple-Negative and Luminal Breast Tumors, Iranian Biomedical Journal (2018)
22. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
23. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)
24. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
25. The Potential of Circulating Tumor Cells in Personalized Management of Breast Cancer: A Systematic Review, Acta Medica Iranica (2017)
26. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review, Pharmacological Reviews (2023)
27. Impact of Microrna Variants on Pi3k/Akt Signaling in Triple-Negative Breast Cancer: Comprehensive Review, Medical Oncology (2024)
28. In Vitro and in Vivo Evaluation of Paclitaxel–Lapatinib-Loaded F127 Pluronic Micelles, Drug Development and Industrial Pharmacy (2017)
29. Assessing the Prognostic Factors, Survival, and Recurrence Incidence of Triple Negative Breast Cancer Patients, a Single Center Study in Iran, PLoS ONE (2019)
30. Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents, Tumor Biology (2016)
31. Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced Her2-Positive Breast Cancer Patients, International Journal of Hematology-Oncology and Stem Cell Research (2021)
32. Chemotherapy: A Double-Edged Sword in Cancer Treatment, Cancer Immunology# Immunotherapy (2022)
33. Horizons of Personalized Medicine in Breast Cancer Treatment: Review Article, Tehran University Medical Journal (2016)
34. The Role of Oncomirs in the Pathogenesis and Treatment of Breast Cancer, Biomedicine and Pharmacotherapy (2016)
35. Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report From Cancer Institute of Iran, International Journal of Hematology-Oncology and Stem Cell Research (2017)